Solidago canadensis L. Herb Extract, Its Amino Acids Preparations and 3D-Printed Dosage Forms: Phytochemical, Technological, Molecular Docking and Pharmacological Research
<b>Background/Objectives</b>: The Canadian goldenrod (<i>Solidago canadensis</i> L.) is one of the most widespread species of the genus <i>Solidago</i> from the Asteraceae family. It has a rich composition of biologically active compounds and is traditionally used to address kidney, urinary tract, and liver diseases. Previously, it was proven that the <i>S. canadensis</i> extract obtained with a 40% ethanol solution had the most promising anti-inflammatory and hepatoprotective activity. Therefore, this extract was selected for the further formulation of amino acid preparations and 3D-printed dosage forms. The aims of the present study were to investigate the chemical composition, toxicity, and antimicrobial, anti-inflammatory, and hepatoprotective activity of <i>S. canadensis</i> dry extract, its amino acid preparations, and 3D-printed dosage forms. <b>Results</b>: A total of 18 phenolic compounds and 14 amino acids were determined in the extracts. The <i>S. canadensis</i> herb extracts were verified to be practically non-toxic preparations (toxicity class V, LD₅₀ > 5000 mg/kg). They also showed moderate antimicrobial activity against <i>Staphylococcus aureus</i>, <i>Enterococcus faecalis,</i> and β-hemolytic <i>Streptococcus pyogenes</i>. The most pronounced hepatoprotective activity was observed with <i>S. canadensis</i> herb extract and its amino acid preparations with phenylalanine, alanine, and lysine at a dose of 25 mg/kg body weight. The most pronounced anti-inflammatory activity was found with <i>S. canadensis</i> herb extract and its preparation with arginine. According to the calculated docking score array and the analysis of binding modes in the active sites of COX-1 and COX-2, the flavonoid fraction and caffeic acid in the <i>S. canadensis</i> extracts presented moderate inhibitory activity. <b>Conclusions</b>: The development of innovative 3D-printed oral dosage forms represents a promising strategy to formulate dietary supplements or pharmaceutical preparations for these herbal extracts.
Authors
- Yurii Hrytsyk (ORCID: https://orcid.org/0000-0003-3006-290X)
- Lyubov Grytsyk (ORCID: https://orcid.org/0000-0003-0338-1462)
- Jyrki Heinämäki (ORCID: https://orcid.org/0000-0002-5996-5144)
- Aіn Raal (ORCID: https://orcid.org/0000-0001-8731-7366)
- Мarharyta Suleiman (ORCID: https://orcid.org/0000-0001-6388-5342)
- Lina Perekhoda (ORCID: https://orcid.org/0000-0002-8498-331X)
- Valdas Jakštas (ORCID: https://orcid.org/0000-0001-7627-6263)
- Vaidotas Žvikas (ORCID: https://orcid.org/0000-0002-3503-9824)
- Oleh Коshovyi (ORCID: https://orcid.org/0000-0001-9545-8548)
- O. І. Yurchyshyn (ORCID: https://orcid.org/0000-0003-4792-3737)
Institutions
- Lithuanian University of Health Sciences (LT)
- Ivano-Frankivsk National Medical University (UA)
- National University of Pharmacy (UA)
- University of Tartu (EE)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2025-03-24
- DOI
- https://doi.org/10.3390/pharmaceutics17040407
- Citations
- 4
- Primary Topic
- Drug-Induced Hepatotoxicity and Protection
- Type
- article
- Field-Weighted Citation Impact
- 6.23
Funders
- European Commission
- Eesti Teadusagentuur
- NordForsk